Audience: Individuals Performing COVID-19 Testing
Level: Laboratory Alert
After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.
Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test.
CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.
Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.
CDC press release /21Jul2021
村松社長
最新記事 by 村松社長 (全て見る)
- 欧州で吹き荒れるストという名の権利(待遇改善・ギャラUP)要求!今度はイギリスの空の玄関口で - 2024年4月19日
- 安全な旅行、安心な旅行を担保するにはそれなりのコストが掛かっているですが、今時の若い人達はそんな事は知った事じゃないと・・・ - 2024年4月18日
- 日本国の旅券(りょけん:パスポート)に記載の氏名が些か旅行代理店には難儀な事に成っています - 2024年4月17日
- 日本での宿泊施設は、此れから居抜き店舗営業が益々多くなんるでしょうね - 2024年4月16日
- 大きなツケは利用者が負う事になるのかも?!膨大な時間と労力と言うツケを?! - 2024年4月15日